Exploring the Synergistic Effects of Erinacines on Microglial Regulation and Alzheimer's Pathology Under Metabolic Stress
2024

Effects of Erinacines on Microglial Regulation and Alzheimer's Disease

Sample size: 6 publication 10 minutes Evidence: moderate

Author Information

Author(s): Bui Van Thanh, Wu Kuan‐Wei, Chen Chin‐Chu, Nguyen Anh Thuc, Huang Wei‐Jan, Lee Li‐Ya, Chen Wan‐Ping, Huang Chi‐Ying, Shiao Young‐Ji

Primary Institution: National Yang Ming Chiao Tung University

Hypothesis

Can erinacines modulate microglial morphology and alleviate Alzheimer's pathology under metabolic stress?

Conclusion

Erinacines enhance microglial ramification and reduce Alzheimer's disease pathology in a metabolically stressed model.

Supporting Evidence

  • Erinacines significantly promoted the development of a ramified, neuroprotective microglial phenotype.
  • Erinacines significantly lower fasting blood glucose and insulin levels.
  • Erinacines reduced amyloid‐beta plaque burden and enhanced neurogenesis in metabolically stressed APP/PS1 mice.
  • Bioinformatics revealed potential modulation of microglia via histone deacetylase inhibition.
  • Erinacines improved memory and behavioral deficits in HFSTZ‐APP/PS1 mice.

Takeaway

This study shows that a mushroom extract can help brain cells look and act healthier, which might help treat Alzheimer's disease.

Methodology

The study used rat primary mixed glial cultures and a metabolically stressed APP/PS1 mouse model to evaluate the effects of erinacines.

Limitations

The study primarily used a specific mouse model, which may not fully represent human Alzheimer's disease.

Participant Demographics

APP/PS1 transgenic mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/cns.70137

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication